Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma & Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female volunteers, aged 18 years and above, with persistent asthma and allergic rhinitis~* On a minimum of 200μg BDP of Inhaled corticosteroid (ICS)~* FEV1 ≥ 60 % predicted~* Positive skin prick test, or record of elevated allergen-specific IgE to at least 1 perennial allergen~* Methacholine PC20 \< 8mg/ml at Visit 1~* Ability to give informed consent~Exclusion Criteria:~* Other respiratory diseases such as COPD, bronchiectasis or allergic bronchopulmonary aspergillosis (ABPA) which are considered to be significant in the opinion of the study physician Nasal polyps ≥ Grade 2~* An asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement, or 3 months if hospital admission was required~* Any clinically significant medical condition that may endanger the health or safety of the participant. For example: Patients who have tuberculosis or any type of untreated infection or have had recent surgical operation or injury to the nose or mouth.~* Participation in another trial within 30 days before the commencement of the study~* Pregnancy or lactation~* Unable to comply with the procedures of the protocol~* Unable or unwilling to consent~* Taking prohibited medications as listed in section 6.7.2 Prohibited Medications~* Hypersensitivity to the active substances or to any of the excipients of Dymista Nasal Spray.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azelastine-Fluticasone Nasal (Type: ACTIVE_COMPARATOR): 137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate per actuation. 1 squirt twice daily
- Placebos (Type: PLACEBO_COMPARATOR): contains the same components as Dymista nasal spray with the exception of the active ingredients. 1 squirt twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).